Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Tobias Lange (Regensburg, Germany), Tobias Lange, Michael Arzt, Michael Pfeifer. Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy?. Eur Respir J 2015; 46: Suppl. 59, 2101

Member's Comments

No comment yet.

Related content which might interest you: Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Sildenafil for treatment of associated pulmonary hypertension in patients with severe COVID-19 pneumonia. Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Effect of long-term specific therapy in a cohort of 33 patients with pulmonary arterial hypertension of various etiologies Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Newly diagnosed patients with chronic thromboembolic pulmonary hypertension and PASP<50 mmHg. Do they need pulmonary endarterectomy? Source: Annual Congress 2005 - News about pulmonary embolism Year: 2005 Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019 Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 Which patients are SaPHe in sarcoidosis-associated pulmonary hypertension? Source: Eur Respir J, 55 (5) 2000700; 10.1183/13993003.00700-2020 Year: 2020 Diagnosis and treatment of secondary pulmonary hypertension in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 404s Year: 2006 Combined treatment in pulmonary hypertension Source: International Congress 2016 – GR3 Scientific Grand Round: precision medicine Year: 2016 Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Clinical characteristics, haemodynamics, and survival in patients with combined pulmonary fibrosis and emphysema and associated pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular medicine Year: 2008 Audit of disease targeted therapies in adult patients with pulmonary arterial hypertension Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Factors associated with survival in patients with not-operated chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension Year: 2018 Outcomes from use of targeted therapy in pulmonary hypertension associated with sarcoidosis (PHAS) Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Successful use of sildenafil in the treatment of pulmonary hypertension in patients with severe non-operable chronic thromboembolic disease Source: Annual Congress 2004 - Treatment of pulmonary hypertension Year: 2004 Does pulmonary hypertension exclude pulmonary rehabilitation in patients with COPD? Source: International Congress 2017 – Best abstracts in pulmonary rehabilitation in patients with chronic lung diseases Year: 2017 Pulmonary hypertension associated with sarcoidosis and experience of treatment with pentoxifylline (Vasonite) Source: Eur Respir J 2006; 28: Suppl. 50, 426s Year: 2006 Disease-targeted treatment improves cognitive function in patients with pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015